At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 18 enrolled

Drug / intervention

DT2219ARLbiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02370160

NCT02370160Phase 2Completed

Compare CT.gov

HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma

Masonic Cancer Center, University of Minnesota·interventional·Posted Feb 24, 2015·Updated Jan 13, 2020

In Brief

A Phase 2 clinical trial evaluating DT2219ARL for Refractory B-Lineage Leukemia and 3 related conditions. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma. The study consists of two phases - a phase I dose/schedule finding component using the maximum tolerated dose identified during the previous phase I study, but with a higher number of doses and a two-stage phase II extension component to confirm safety and make a preliminary determination of the activity level by disease using the dose identified in phase I.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsRefractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Lymphoma

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

First PostedFeb 2015

Enrollment StartDec 2015

Primary CompletionApr 2018

TodayJul 2026

First PostedFeb 24, 2015

Enrollment StartDec 21, 2015

Primary CompletionApr 8, 2018

TodayJul 2, 2026

Enrollment to primary: 2.3 yearsPosted 11.4 years ago

Interventions

DT2219ARLbiological

DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.